Genetic neuroendocrine tumor

Genetic neuroendocrine tumors (NETs) refer to neuroendocrine neoplasms that arise in the context of hereditary predisposition syndromes caused by germline mutations in specific genes. Neuroendocrine tumors develop from neuroendocrine cells found throughout the body, most commonly in the gastrointestinal tract, pancreas, and lungs. When occurring as part of a genetic syndrome, they may be associated with conditions such as Multiple Endocrine Neoplasia type 1 (MEN1), Multiple Endocrine Neoplasia type 2 (MEN2), Von Hippel-Lindau disease (VHL), Neurofibromatosis type 1 (NF1), or Tuberous Sclerosis Complex (TSC), among others. These hereditary forms tend to present at younger ages and may be multifocal compared to sporadic neuroendocrine tumors. The clinical presentation of genetic neuroendocrine tumors varies widely depending on the underlying syndrome and the location of the tumors. Symptoms may include hormonal hypersecretion leading to flushing, diarrhea, wheezing, hypoglycemia, peptic ulcers (as in Zollinger-Ellison syndrome), or Cushing syndrome, depending on the hormones produced. Some tumors are non-functional and may present with mass effects, abdominal pain, or be discovered incidentally. Affected body systems include the endocrine system, gastrointestinal tract, respiratory system, and potentially the central nervous system. Management of genetic neuroendocrine tumors requires a multidisciplinary approach including surveillance protocols tailored to the specific hereditary syndrome, surgical resection when feasible, somatostatin analogs for symptom control and tumor growth inhibition, targeted therapies such as everolimus or sunitinib, peptide receptor radionuclide therapy (PRRT), and chemotherapy in selected cases. Genetic counseling and cascade testing of at-risk family members are essential components of care. Early detection through syndrome-specific screening programs can significantly improve outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic neuroendocrine tumor